Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis – Translational Neurodegeneration
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the selective loss of motor neurons (MNs), resulting in progressive disability and mortality with a rapid course. Current approaches such as multidisciplinary care, disease-modifying therapies, pulmonary in tervention, and dietary and nutritional intervention can only slow ALS progression [1]. It is imperative to dissect the underlying mechanisms and explore novel treatment targets. Trans-reactive DNA binding protein 43